Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders

  • George Diaz

Press/Media

Period7 Apr 2019

Media coverage

1

Media coverage

  • TitleAeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
    Media name/outletPrimeNewswire (Top News)
    Country/TerritoryUnited States
    Date7/04/19
    PersonsGeorge Diaz
View all 1
View less